Based on the information provided, I was unable to find specific risks associated with taking Cosentyx (secukinumab) after vaccination. However, it is generally recommended to consult with a healthcare provider before starting any new medication, including Cosentyx, after receiving a vaccine. This is to ensure the safety and efficacy of both the vaccine and the medication.

Cosentyx is a medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body that causes inflammation.

Vaccines work by stimulating the immune system to produce a response to protect against future infections. It is important to note that some vaccines may not be as effective in individuals taking certain medications, such as Cosentyx, that affect the immune system.

According to DrugPatentWatch.com, Cosentyx is a medication that is still under patent protection, and is manufactured by Novartis. The patent for Cosentyx is set to expire in 2027, which may lead to the introduction of generic versions of the medication.

In summary, while there is no specific information available regarding the risks of taking Cosentyx after vaccination, it is always recommended to consult with a healthcare provider before starting any new medication after receiving a vaccine.

Sources:

* [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/cosentyx). Cosentyx (secukinumab) Drug Patent Information. DrugPatentWatch.com.
* Mayo Clinic. (2021). Secukinumab (Injection route). Mayo Clinic.
* U.S. National Library of Medicine. (2021). Secukinumab. MedlinePlus.
* U.S. Food and Drug Administration. (2021). Cosentyx (secukinumab) injection, for subcutaneous use. U.S. Food and Drug Administration.